April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Combined Blockade of VEGFR-3 and VLA-1 Promotes High-Risk Corneal Transplant Survival
Author Affiliations & Notes
  • L. Chen
    Center for Eye Disease and Development, Program in Vision Science, University of California, Berkeley, Berkeley, California
  • H. Zhang
    Center for Eye Disease and Development, Program in Vision Science, University of California, Berkeley, Berkeley, California
  • D. Yuen
    Center for Eye Disease and Development, Program in Vision Science, University of California, Berkeley, Berkeley, California
  • Footnotes
    Commercial Relationships  L. Chen, None; H. Zhang, None; D. Yuen, None.
  • Footnotes
    Support  This work is supported in part by research grants from NIH, DoD, and University of California at Berkeley.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1556. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Chen, H. Zhang, D. Yuen; Combined Blockade of VEGFR-3 and VLA-1 Promotes High-Risk Corneal Transplant Survival. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1556.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Though corneal transplantation enjoys a low rejection rate of 10% in uninflamed recipient corneas or "low-risk" setting, the rejection rate of corneal grafts on the inflamed and highly vascularized recipient corneas or "high-risk" setting can be as high as 90%. To date, there is no effective treatment for this condition. Previous studies have demonstrated that single treatment of VEGFR-3 (vascular endothelial growth factor receptor-3) or VLA-1 (very late antigen-1) suppressed corneal graft rejection in the "low-risk" setting. This study is to determine whether a combined blockade of VEGFR-3 and VLA-1 will promote "high-risk" transplant survival.

Methods: : High-risk corneal transplantation was performed between normal C57BL/6 (donor) and inflamed BALB/c (recipient) mice. The recipients were randomized to receive intraperitoneal injection of the VEGFR-3 (provided by ImClone Systems, New York) and VLA-1 neutralizing antibodies (provided by Covella Pharmaceuticals, Inc.) or their controls twice a week on the day of suture placement and thereafter for 10 weeks. Corneal grafts were evaluated by ophthalmic slit-lamp biomicroscopy and analyzed by Kaplan-Meier survival curve.

Results: : Compared to those of the control group, the transplants in the treatment group demonstrated a greater degree of transparency and a higher rate of survival.

Conclusions: : Combined blockade of VEGFR-3 and VLA-1 may provide a new strategy to promote high-risk corneal transplant survival. Further studies are undertaken to determine possible underlying mechanisms of this significant effect.

Keywords: immunomodulation/immunoregulation • transplantation • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×